1.545
price up icon1.31%   0.02
 
loading
Schlusskurs vom Vortag:
$1.525
Offen:
$1.51
24-Stunden-Volumen:
26,202
Relative Volume:
0.31
Marktkapitalisierung:
$141.46M
Einnahmen:
$5.15M
Nettoeinkommen (Verlust:
$-65.35M
KGV:
-1.1444
EPS:
-1.35
Netto-Cashflow:
$-20.85M
1W Leistung:
+5.10%
1M Leistung:
+5.82%
6M Leistung:
-14.17%
1J Leistung:
-20.16%
1-Tages-Spanne:
Value
$1.51
$1.62
1-Wochen-Bereich:
Value
$1.40
$1.62
52-Wochen-Spanne:
Value
$1.10
$2.43

Cellectis Adr Stock (CLLS) Company Profile

Name
Firmenname
Cellectis Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
222
Name
Twitter
@cellectis
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
CLLS's Discussions on Twitter

Vergleichen Sie CLLS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CLLS
Cellectis Adr
1.58 141.46M 5.15M -65.35M -20.85M -1.35
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.90 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
542.36 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
318.33 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
559.15 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
242.56 28.51B 3.81B -644.79M -669.77M -6.24

Cellectis Adr Stock (CLLS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-03-17 Eingeleitet Bryan Garnier Buy
2022-05-18 Hochstufung Robert W. Baird Neutral → Outperform
2022-01-06 Herabstufung Wells Fargo Overweight → Equal Weight
2021-11-30 Eingeleitet JMP Securities Mkt Outperform
2021-11-08 Herabstufung William Blair Outperform → Mkt Perform
2021-10-08 Herabstufung Robert W. Baird Outperform → Neutral
2021-04-28 Herabstufung Guggenheim Buy → Neutral
2021-03-16 Hochstufung Robert W. Baird Neutral → Outperform
2020-08-19 Hochstufung Citigroup Neutral → Buy
2020-05-12 Eingeleitet Robert W. Baird Outperform
2020-03-06 Herabstufung Goldman Neutral → Sell
2019-10-30 Fortgesetzt Guggenheim Buy
2019-08-09 Eingeleitet BTIG Research Buy
2019-05-24 Fortgesetzt Citigroup Neutral
2019-03-14 Eingeleitet William Blair Outperform
2018-12-19 Eingeleitet Goldman Neutral
2018-07-16 Eingeleitet Barclays Overweight
2018-03-16 Eingeleitet Guggenheim Neutral
2017-09-05 Herabstufung SunTrust Buy → Hold
2017-09-05 Bestätigt Wells Fargo Outperform
2017-03-02 Eingeleitet Instinet Buy
2017-02-28 Eingeleitet Wells Fargo Outperform
2016-04-05 Eingeleitet Ladenburg Thalmann Buy
2016-03-02 Eingeleitet Sun Trust Rbsn Humphrey Buy
2015-07-20 Eingeleitet BofA/Merrill Buy
2015-04-20 Eingeleitet Jefferies Buy
2015-04-20 Eingeleitet Piper Jaffray Overweight
Alle ansehen

Cellectis Adr Aktie (CLLS) Neueste Nachrichten

pulisher
Jun 16, 2025

European Stocks Shine As ADRs Climb Higher - Finimize

Jun 16, 2025
pulisher
Jun 13, 2025

European ADRs Dip With Some Stocks Rising Above The Crowd - Finimize

Jun 13, 2025
pulisher
May 26, 2025

Cellectis’s SWOT analysis: gene therapy firm’s stock faces pivotal year By Investing.com - Investing.com South Africa

May 26, 2025
pulisher
May 26, 2025

Cellectis’s SWOT analysis: gene therapy firm’s stock faces pivotal year - Investing.com

May 26, 2025
pulisher
May 21, 2025

Cellectis S.A. announces board change and meeting By Investing.com - Investing.com India

May 21, 2025
pulisher
May 21, 2025

Cellectis S.A. announces board change and meeting - Investing.com

May 21, 2025
pulisher
May 15, 2025

European Equities See Growth In US Trade - Finimize

May 15, 2025
pulisher
May 13, 2025

Cellectis earnings beat by $0.07, revenue topped estimates - Investing.com

May 13, 2025
pulisher
May 12, 2025

Cellectis earnings beat by $0.06, revenue topped estimates - Investing.com India

May 12, 2025
pulisher
Apr 22, 2025

Cellectis Charts Course For 2025 With Boost From AstraZeneca Deal - Barchart.com

Apr 22, 2025
pulisher
Apr 11, 2025

European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading - TradingView

Apr 11, 2025
pulisher
Apr 08, 2025

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView

Apr 08, 2025
pulisher
Apr 04, 2025

Cellectis stock touches 52-week low at $1.14 amid market challenges - Investing.com

Apr 04, 2025
pulisher
Apr 02, 2025

European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - TradingView

Apr 02, 2025
pulisher
Mar 20, 2025

European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading - TradingView

Mar 20, 2025
pulisher
Mar 18, 2025

European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - TradingView

Mar 18, 2025
pulisher
Mar 17, 2025

European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Cellectis’s SWOT analysis: biotech firm’s stock faces CAR T challenges - Investing.com

Mar 17, 2025
pulisher
Mar 15, 2025

Earnings call transcript: Cellectis beats Q4 2024 expectations, stock up 10% By Investing.com - Investing.com South Africa

Mar 15, 2025
pulisher
Mar 14, 2025

Cellectis stock touches 52-week low at $1.2 amid market challenges - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Earnings call transcript: Cellectis beats Q4 2024 expectations, stock up 10% - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

What Recent Market Trends Mean for Cosan S.A ADR’s (CSAN) Stock - The News Heater

Mar 14, 2025
pulisher
Mar 11, 2025

European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading - TradingView

Mar 11, 2025
pulisher
Mar 07, 2025

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up Slightly for Week - TradingView

Mar 07, 2025
pulisher
Mar 06, 2025

Cellectis stock touches 52-week low at $1.24 amid market challenges - Investing.com India

Mar 06, 2025
pulisher
Mar 06, 2025

European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading - TradingView

Mar 06, 2025
pulisher
Feb 28, 2025

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView

Feb 28, 2025
pulisher
Feb 27, 2025

StockNews.com Begins Coverage on Cellectis (NASDAQ:CLLS) - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Cellectis earnings missed by $0.20, revenue fell short of estimates - Investing.com

Feb 27, 2025
pulisher
Feb 25, 2025

Cellectis stock touches 52-week low at $1.4 amid market challenges By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 25, 2025

Cellectis stock touches 52-week low at $1.4 amid market challenges - Investing.com India

Feb 25, 2025
pulisher
Feb 24, 2025

Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 - GlobeNewswire Inc.

Feb 24, 2025
pulisher
Feb 14, 2025

European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Up 1% for Week - TradingView

Feb 14, 2025
pulisher
Feb 07, 2025

European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, End Week Up 3.2% - TradingView

Feb 07, 2025
pulisher
Jan 03, 2025

This Penny Stock Has 270% Upside Potential In 2025. Is It A Buy Now? - Barchart

Jan 03, 2025
pulisher
Dec 29, 2024

Analysts Predict 400% Upside Potential for This Penny Stock - Yahoo Finance

Dec 29, 2024
pulisher
Dec 26, 2024

Cellectis stock plunges to 52-week low at $1.52 amid market challenges - Investing.com India

Dec 26, 2024
pulisher
Dec 16, 2024

Cellectis stock touches 52-week low at $1.7 amid market challenges - Investing.com

Dec 16, 2024
pulisher
Dec 15, 2024

Cellectis's SWOT analysis: CAR T pioneer's stock faces pivotal year - Investing.com

Dec 15, 2024
pulisher
Nov 25, 2024

Cellectis's SWOT analysis: CAR T pioneer's stock faces pivotal year ahead - Investing.com

Nov 25, 2024
pulisher
Nov 05, 2024

Baird maintains $10 target on Cellectis amid strong AZN partnership - Investing.com

Nov 05, 2024
pulisher
Aug 01, 2023

CellectisADR (CLLS) Price Target Increased by 7.35% to 11.62 - Nasdaq

Aug 01, 2023
pulisher
Jun 30, 2022

Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing - Nature

Jun 30, 2022
pulisher
Feb 26, 2021

Biotech Stocks Rise After FDA Halts Test By Rival Blood Cancer Firm Cellectis - Investor's Business Daily

Feb 26, 2021

Finanzdaten der Cellectis Adr-Aktie (CLLS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.91
price up icon 1.21%
$36.18
price up icon 0.58%
$20.72
price down icon 2.91%
$99.33
price down icon 1.11%
$107.07
price up icon 0.55%
biotechnology ONC
$242.60
price up icon 0.07%
Kapitalisierung:     |  Volumen (24h):